Eledon Pharmaceuticals, Inc. (ELDN) key performance indicators and operating metrics (7 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Mean Estimated Glomerular Filtration Rate at Twenty-Four Months | 74.20 ratio | FY2026-Q1 |
| Non-Cash Loss From Changes in Fair Value of Warrant Liabilities | 19M | FY2026-Q1 |
| Cash, Cash Equivalents, and Short-Term Investments Excluding Private Placement Proceeds | 93.4M | FY2025-Q3 |
| Net Proceeds From Underwritten Offering | 53.6M | FY2025-Q3 |
| Total Gross Proceeds From Underwritten Offering | 57.5M | FY2025-Q3 |
| Estimated Glomerular Filtration Rate at Twelve Months | 69.00 ratio | FY2025-Q3 |
| Mean Estimated Glomerular Filtration Rate at Twelve Months After Acute Rejection on Tegoprubart | 73.00 ratio | FY2025-Q3 |
Back to ELDN overview · ELDN earnings · ELDN holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.